Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Tebipenem HBr in Subjects with Renal Impairment
NCT04178577Phase 1Completed
- Sponsor
- Spero Therapeutics
- Start
- Dec 2019
- Primary completion
- Sep 2020
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tebipenem in complicated urinary tract infection (cUTI) and acute pyelonephritis, sponsored by Spero Therapeutics. Primary endpoints: Apparent total body clearance, Area under the curve from time zero to the last quantifiable sample and 5 more. Started Dec 2019; status: completed.
02
Drugs
tebipenem
03
Conditions
complicated urinary tract infection (cUTI)acute pyelonephritis
Beyond the preview
Go deeper on NCT04178577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178577.